invIOs

Executive Summary

invIOs is a private Austrian biotechnology company focused on developing next-generation cancer immunotherapies for solid tumors. Founded in 2018 and launched in 2022 as a spin-out from APEIRON Biologics, the company combines cell therapies and small molecules to address high-unmet-need cancers. Its lead programs are in Phase 1 development, targeting novel immune evasion pathways. The company's differentiated approach aims to empower the immune system by targeting both tumor-intrinsic and microenvironmental resistance mechanisms. With a pipeline centered on novel biologics and small-molecule immunomodulators, invIOs has potential to offer new options for patients who do not respond to current checkpoint inhibitors or CAR-T therapies. However, as a private, early-stage company with no disclosed funding or valuation, visibility is limited, and execution risk remains significant. The coming 1–2 years will be critical as the company advances its lead candidates through early clinical trials and seeks to establish proof-of-concept.

Upcoming Catalysts (preview)

• H2 2026Phase 1 interim data for lead cell therapy candidate35% success
• Q1 2027IND filing for next small molecule program40% success
• TBDPotential partnership or funding round to support pipeline expansion50% success